Expansion in the DMPK/Tox field

「Pharmacology 66,409 90.8 / Safety-related fields 1,499,123 102.1」

「As new drug-discovery modalities emerge, use of PXB mice in the development of nucleic acid medicines, gene therapies and other products has increased, and inquiries from new customers have also increased as their usefulness has become more widely recognized.」

「However, contract testing services in the hepatitis field have recently declined substantially, and a recovery in the market is not expected. The Group is therefore working to expand the use of PXB mice and PXB-cells in the larger safety-related market, which covers nearly all drug candidate substances.」

「Demand for PXB mice has shifted from the hepatitis field to biopharmaceuticals, and their use in the development of nucleic acid medicines, gene therapies and other products has increased. However, during the interim consolidated accounting period, research and development activity declined markedly among overseas pharmaceutical companies, the Group's major customers, as development programs were frequently cancelled and headcount reductions were implemented. Although inquiries continued to be received, order intake remained challenging and substantially below the previous year, while revenue also fell below the previous year because of the decline in new orders.」

「Overall order intake exceeded the same period of the previous year. In the safety-related field, PXB mice have gained recognition as a useful tool in the development of nucleic acid medicines, gene therapies and other pharmaceuticals, and order intake substantially exceeded the previous year following the acquisition of a large mouse-sales order.」

「Overall order intake exceeded the same period of the previous year. In the safety-related field, mouse sales and other business remained firm, and demand for PXB mice for nucleic acid medicines also remained stable, resulting in a substantial year-on-year increase.」

「Demand for PXB mice among pharmaceutical companies and research institutions, the Group's major customers, has increased, particularly in overseas markets, and the Group has received many inquiries. Order intake in the pharmacology field fell below the same period of the previous year because development delays and cancellations occurred in projects involving anti-hepatitis B drugs. In the safety-related field, however, order intake, including mouse sales, exceeded the previous year as orders were secured broadly in line with the plan.」

「The Group regards revenue by field as an important management indicator. Safety-related fields 1,127,751 139.4」

「Demand for PXB mice among pharmaceutical companies and research institutions, the Group's major customers, has remained firm, particularly in overseas markets, with strong inquiry activity in both the pharmacology and safety-related fields.」

「Demand for PXB mice among the Group's principal customers, pharmaceutical companies and research institutions, remained solid, particularly in overseas markets, and the Group received many inquiries in both the pharmacology and efficacy evaluation and safety-related fields. Orders declined from the prior-year period, when several large projects were secured, but the order backlog remained at a high level.」

「Demand for PXB mice among the Group's principal customers, pharmaceutical companies and research institutions, remained strong, particularly in overseas markets, and the Group received many inquiries in both the pharmacology and efficacy evaluation and safety-related fields. Orders declined from the prior-year period, when several large projects were secured, but the order backlog remained at a high level.」

「In addition to its long-standing track record in efficacy evaluation of anti-hepatitis B virus drugs, the Company's PXB mice are increasingly being used in biopharmaceutical fields, including nucleic acid drugs. Orders and the order backlog for the fiscal year ending March 2022 reached record highs.」

「Under these circumstances, during the fiscal year ending March 2022, the Group will use the consortium and strengthen cooperation with CROs in Japan and overseas to develop the market for PXB mice. As of the fiscal year ended March 2021, 11 organizations were participating in the consortium established in the United States as a forum for jointly researching the usefulness of PXB mice with pharmaceutical companies.」

「Although laboratory operations in Japan and overseas at the Group's principal customers, pharmaceutical companies and research institutions, gradually resumed as economic activity restarted, research and development activities remained stalled in the United States and some parts of Europe, where COVID-19 infections were spreading. As a result, revenue and orders in both the pharmacology and efficacy evaluation and safety-related fields fell below the prior-year period.」

「In the safety-related fields that the Group has positioned as growth areas, intensified sales activities targeting overseas pharmaceutical companies focused on developing biopharmaceuticals, including nucleic acid drugs for which demand for PXB mice is expected, began to bear fruit, enabling the Group to continue securing orders. Overseas revenue grew substantially, and total revenue reached a record high, offsetting the decline in the pharmacology and efficacy evaluation field.」

「In safety-related fields, which the Group positions as growth areas because they can target many new drugs, orders related to nucleic acid drugs in overseas markets, where the Group is pursuing market development, grew substantially, and orders and revenue exceeded the prior-year period.」

「In safety-related fields, which the Group positions as growth areas because they can target many new drugs, orders related to nucleic acid drugs grew in overseas markets, and orders and revenue exceeded the prior-year period.」

「In safety-related fields, which the Group positions as growth areas because they can target many new drugs, orders and revenue exceeded the prior-year period as the Group secured more orders than planned in overseas markets.」

「In DMPK/Tox testing, which the Group positions as a growth area because it can target many new drugs, testing using PXB mice increased in the biopharmaceutical field, which is attracting attention as a new generation of pharmaceuticals. Revenue and orders exceeded the prior-year period.」

「In DMPK/Tox testing and other areas, which the Group positions as growth areas because they can target many new drugs, the Group lost an expected annual contract for PXB-cells, but orders in the nucleic acid drug field, which is attracting attention as a new generation of pharmaceuticals, increased. Revenue and orders were therefore above the prior-year period.」

「In DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) and other areas, which the Group positions as growth areas because they can target many new drugs, both orders and revenue exceeded the prior-year period, but fell short of the initial plan due to testing delays and lower sales of PXB-cells.」

「In DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) and other areas, which the Group positions as growth areas because they can target many new drugs, orders in the chemicals field and sales of PXB-cells grew following useful academic presentations, while sales of PXB mice in overseas markets were weak.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a growth area because it can target many new drugs. The Group established CMHL Consortium LLC as a forum for validating the usefulness of PXB mice and conducts joint research with pharmaceutical companies and others.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a growth area because it can target many new drugs. The Group established CMHL Consortium LLC as a forum for validating the usefulness of PXB mice and conducts joint research with pharmaceutical companies and others.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a growth area because it can target many new drugs. The Group established the consortium CMHL Consortium LLC as a forum for validating the usefulness of PXB mice and conducts joint research with pharmaceutical companies and others. Research on PXB mice presented at academic conferences and in papers promotes the mice to researchers at pharmaceutical companies and others, helping raise awareness of PXB mice in the broad DMPK/Tox field. Although domestic revenue remained firm as research results presented at a domestic academic conference in the previous fiscal year led to orders, overseas revenue got off to a slow start.」

「The DMPK/Tox field targeted by the Company is a large market, and the Company believes there is demand for its PXB mice. Accordingly, the Company established a consortium in North America as a forum where pharmaceutical companies with numerous drug candidates can jointly research the usefulness of PXB mice and share the results. During the fiscal year, the Company began researching the usefulness of PXB mice with overseas pharmaceutical companies.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」

「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」

「The Group's efficacy evaluation testing for hepatitis treatments, in which it has built a track record, serves a limited market and may decline depending on the status of new drug development. By contrast, the DMPK/Tox field targeted by the Company is a large market, and the Company believes there is demand for its PXB mice.」